HER2 and PI3K-targeted therapies result in FOXO3a-mediated feedback upregulation of HER3 and IGF1R and provide an escape from PI3K pathway inhibition.

Slides:

Advertisements

Similar presentations

Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.

Advertisements

Dietary cancer-chemopreventive compounds: from signaling and gene expression to pharmacological effects Chi Chen, Ah-Ng Tony Kong Trends in Pharmacological.

Mouse Double Minute 2 (MDM2)

Combination with IGF1R, PI3K inhibitors

Targeting signal transduction

John W. Bloom, MD Journal of Allergy and Clinical Immunology

Juewon Kim, Hyunjung Choi, Eun-Gyung Cho, Tae R. Lee

Figure 1 Cellular processes involved in cancer development

Sustaining Proliferative Signaling and Evading Growth Suppressors

MAPK pathway inhibitors.

Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell

Genetic alterations in the PI3K–PTEN–AKT pathway detected during disease progression and their functional impacts. Genetic alterations in the PI3K–PTEN–AKT.

PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation. PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation.

Figure 4 Possible combination therapies CDK4/6 inhibitors

The Akt-mTOR tango and its relevance to cancer

Figure 1 A schematic representation of the HER2 signalling pathway

Volume 56, Issue 3, Pages (March 2012)

Figure 2 Oestrogen receptor signalling pathways

Nat. Rev. Urol. doi: /nrurol

Sohlh2 inhibits the apoptosis of mouse primordial follicle oocytes via C- kit/PI3K/Akt/Foxo3a signalling pathway Xiaoli Zhang, Haiyu Zhang, Qing Gao,

therapy and to block androgen action

Targeted Therapies in Melanoma: Translational Research at Its Finest

Caught in the Akt: Regulation of Wnt Signaling in the Intestine

Figure 1 The role of CTLA4 and PD1 in T cell activation

A New Twist in Smad Signaling

Volume 22, Issue 6, Pages (December 2012)

Taru Muranen, Funda Meric-Bernstam, Gordon B. Mills Cancer Cell

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Nephrol. doi: /nrneph

Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer Thomas Winder, Heinz–Josef.

The RAS/MAPK Axis Gets Stressed Out

Youry Kim, Jenny L. Anderson, Sharon R. Lewin Cell Host & Microbe

NOTCH and PI3K-AKT Pathways Intertwined

Activated membrane signaling promotes survival in response to radiation. Activated membrane signaling promotes survival in response to radiation. Radiation.

Coactivation of Receptor Tyrosine Kinases in Malignant Mesothelioma as a Rationale for Combination Targeted Therapy Marie Brevet, MD, PhD, Shigeki Shimizu,

NF-κB activation in pathogenesis and therapy of cancer.

p38 MAPK activation is required for phosphorylation of Akt at Ser473.

Figure 4 Bile-acid-induced TGR5 signalling pathways in macrophages

Nat. Rev. Urol. doi: /nrurol

Genes frequently mutated in colorectal cancer and their relationships with miRNAs. Genes frequently mutated in colorectal cancer and their relationships.

Summary of this study. Summary of this study. Cysteinyl-leukotrienes (cys-LTs) stimulate mitogenesis of bronchial fibroblasts only in the presence of RTK.

Figure 2 Signalling downstream of the IL-6 receptor

Friends with Benefits: Microenvironmental NRG1β and HGF Mediate HER2-Targeted Resistance in L-HER2+ and HER2E Breast Cancer Sarah B. Crist, Cyrus M.

Model for insulin-mediated inhibition of adrenomedullin transcription and its consequences on adipocyte differentiation. Model for insulin-mediated inhibition.

Schematic representation of signaling pathways modulated by PKD1 in cancer. Schematic representation of signaling pathways modulated by PKD1 in cancer.

Signaling by Ras/Raf/ERK in the regulation of β-cell proliferation.

Oncogenic indel hotspots.

Down-regulation of the erbB-2 receptor by trastuzumab decreases Akt kinase activation but not MAPK activation. Down-regulation of the erbB-2 receptor by.

Simplified BRAF signaling network.

Potential model of HMQ1611 inhibiting breast cancer cell proliferation

Changes in signal transduction pathway induced by gefitinib.

High-throughput drug screen (HTDS) reveals ARS1620 and PI3K pathway inhibitors synergies and a heterogeneous pattern of RTK synergies. High-throughput.

The critical roles of miR-23a and miR-27a in colorectal cancer progression. miR-23a primarily increases cell motility through downregulation of its target.

Characterization of the MM.1 human multiple myeloma (MM) cell lines

High nuclear β-catenin levels confer resistance to AKT inhibition and coordinates with increased nuclear FOXO3a to promote metastasis in colon cancer.

Successful targeting of ErbB2 receptors—is PTEN the key?

Connections between insulin/insulin-like growth factor 1 signaling and metabolic pathways in tumor cells. Connections between insulin/insulin-like growth.

Overview of molecular JAK signaling.

Compartmentalized cellular functions of KDM4A.

Cell-autonomous mechanisms of resistance to targeted therapies involving the HGF/MET axis. Cell-autonomous mechanisms of resistance to targeted therapies.

An overview of the MAPK signaling pathway with points of therapeutic intervention indicated. An overview of the MAPK signaling pathway with points of therapeutic.

Regulation of signaling by wild-type and oncogenic Ras.

EPHA2 inhibitors inhibit phosphorylation of AKT and ERK, arrest cell cycle at G0–G1, and induce apoptosis in both vemurafenib (VEM)-sensitive and VEM-resistant.

Integrated analysis of gene expression and copy number alterations.

Turning Reciprocal Feedback Regulation into Combination Therapy

Therapeutic strategies for different classes of BRAF and MEK mutations

AXL is not necessary for maintenance of intrinsic resistance.

MITF-low/NF-κB–high transcriptional class is present and associated with resistance to MAPK pathway inhibition in human tumors. MITF-low/NF-κB–high transcriptional.

Skp2, the FoxO1 hunter Cancer Cell

Tackling Resistance to PI3K Inhibition by Targeting the Epigenome

Presentation transcript:

HER2 and PI3K-targeted therapies result in FOXO3a-mediated feedback upregulation of HER3 and IGF1R and provide an escape from PI3K pathway inhibition. HER2 and PI3K-targeted therapies result in FOXO3a-mediated feedback upregulation of HER3 and IGF1R and provide an escape from PI3K pathway inhibition. A, in the basal state, AKT-mediated FOXO3a phosphorylation inhibits translocation of FOXO3a to the nucleus and provides a basal inhibition of RTK synthesis. B, in the presence of PI3K inhibition, via either upstream RTK blockade or small molecule inhibitors, decreased AKT activity allows FOXO3a to translocate to the nucleus and effect transcription of FOXO3a target genes, including HER3 and IGF1R. The increased RTK expression mediates resistance to PI3K inhibition by increasing input into the PI3K pathway and alternate growth pathways, including MAPK. Dotted lines represent multiple steps not shown graphically; line strength represents relative activation. HER2, human epidermal growth factor receptor 2; HER3, human epidermal growth factor receptor 3; FOXO3a, forkhead box O3a. Samuel J. Klempner et al. Cancer Discovery 2013;3:1345-1354 ©2013 by American Association for Cancer Research